Montelukast Puren (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from causing bronchoconstriction, mucus production, and inflammation in the airways, which helps keep breathing easier.

The dosage of Montelukast Puren is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy are limited, and it is classified as a drug with unknown pregnancy risk. It is also excreted in breast milk, so use only if the potential benefit justifies any possible risk to the infant.

To place an order, submit an enquiry on the Montelukast Puren product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic components, but it does not replace rescue inhalers for acute attacks.

Montelukast Puren should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Montelukast Puren is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, and the timing (e.g., in the evening) may be recommended by the prescriber based on the specific indication.

Serious risks include mood changes such as depression, anxiety, or suicidal thoughts, as well as rare allergic reactions like rash, hives, or swelling of the face. Any new or worsening psychiatric symptoms should be reported to a healthcare professional immediately.

Montelukast is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe hepatic impairment, and it is not recommended for children under the approved age for specific indications without medical supervision.